Additionally, the fact that in both cell models, MRP4 modulation alters EGFR score, which is associated with malignant transformation of pancreatic cancer and plays important roles in liver metastases and recurrence of human pancreatic cancer12, indicates that targeting MRP4 could eventually serve as a novel therapeutic strategy in PDAC. Here, EGFR is linked to familial pancreatic carcinoma.